Previous close | 53.25 |
Open | 53.39 |
Bid | 53.81 x 900 |
Ask | 54.72 x 900 |
Day's range | 53.39 - 54.47 |
52-week range | 47.58 - 71.07 |
Volume | |
Avg. volume | 16,870,439 |
Market cap | 109.663B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 14.05 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.40 (4.43%) |
Ex-dividend date | 04 Apr 2024 |
1y target est | N/A |
PRINCETON, N.J., March 28, 2024--Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint....
PRINCETON, N.J., March 28, 2024--BMS Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia in Patients with Moderately to Severely Active Crohn’s Disease
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha